Cardinal Health (CAH) Q3 FY25 earnings call

Cardinal Health delivered strong Q3 FY25 results, driven by robust performance in its Pharmaceutical and Specialty Solutions segment and significant growth in its 'Other' businesses. The company raised its full-year EPS guidance and anticipates double-digit non-GAAP EPS growth in FY26, despite navigating potential tariff impacts and a dynamic macro environment. Management emphasized strategic investments and operational execution across all segments.